Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
Publication|Articles|December 8, 2025
Supplements and Featured Publications
- Integrating MDM2 Inhibition Into Myelofibrosis Management
- Volume 1
- Issue 1
Identifying Early Loss of JAK Inhibitor Response in Myelofibrosis: Current and Emerging Predictors
Identifying Early Loss of JAK Inhibitor Response in Myelofibrosis: Current and Emerging Predictors
Advertisement
Articles in this issue
Advertisement
Related to this article
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
4
Dr Hurvitz on SERENA-6 and Weighing an Early Switch to Camizestrant in Breast Cancer
5